Cullen/Frost Bankers, Inc. Incyte Corp Transaction History

Cullen/Frost Bankers, Inc.

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 05, 2023	SELL	$70.23 - $86.01 $632 - $774	-9 Reduced 26.47%	25 $1,000
Q3 2022 Nov 07, 2022	BUY	$66.18 - $82.86 $595 - $745	9 Added 36.0%	34 $2,000
Q4 2021 Feb 07, 2022	SELL	$63.34 - $74.11 $6,334 - $7,411	-100 Reduced 80.0%	25 $2,000
Q3 2021 Nov 04, 2021	SELL	$68.67 - $84.02 $2,678 - $3,276	-39 Reduced 23.78%	125 $9,000
Q2 2021 Aug 05, 2021	BUY	$79.87 - $87.53 $3,114 - $3,413	39 Added 31.2%	164 $14,000
Q1 2021 May 05, 2021	SELL	$76.02 - $100.5 $608 - $804	-8 Reduced 6.02%	125 $10,000
Q4 2020 Feb 08, 2021	SELL	$80.74 - $97.7 $1,534 - $1,856	-19 Reduced 12.5%	133 $12,000
Q3 2020 Nov 05, 2020	BUY	$85.07 - $109.69 $1,616 - $2,084	19 Added 14.29%	152 $14,000
Q1 2020 May 01, 2020	SELL	$63.18 - $85.97 $1,895 - $2,579	-30 Reduced 18.4%	133 $10,000
Q4 2019 Feb 06, 2020	SELL	$73.04 - $95.72 $4,236 - $5,551	-58 Reduced 26.24%	163 $14,000
Q3 2019 Nov 01, 2019	SELL	$72.82 - $86.52 $655 - $778	-9 Reduced 3.91%	221 $16,000
Q1 2019 Apr 30, 2019	BUY	$63.56 - $88.17 $14,618 - $20,279	230 New	230 $20,000
Q2 2018 Jul 27, 2018	SELL	$60.85 - $83.98 $744,986 - $1.03 Million	-12,243 Closed	0 $0
Q1 2018 May 11, 2018	SELL	$83.06 - $100.98 $3.03 Million - $3.68 Million	-36,461 Reduced 74.86%	12,243 $1.02 Million
Q4 2017 Jan 31, 2018	SELL	$93.56 - $116.6 $270,949 - $337,673	-2,896 Reduced 5.61%	48,704 $4.61 Million
Q3 2017 Nov 02, 2017	BUY	$109.15 - $138.27 $5.63 Million - $7.13 Million	51,600	51,600 $6.02 Million

642

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $15.8B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Cullen/Frost Bankers, Inc., based on Form 13F filings with the SEC.

Stay updated on Cullen/Frost Bankers, Inc. with notifications on news.